Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 147-148

  Holloway, Robert W ^a  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LETTER; OVARY CARCINOMA; PRIORITY JOURNAL;

DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; FEMALE; HUMANS; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 70749130293     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.027     Document Type: Letter

References (10)

1. Karam A.K., Chiang J.W., Fung E., Nosso V., and Karlan B.Y. Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer. Gynecol. Oncol. 114 (2009) 246-252
2. Holloway R.W., Mehta R.S., Finkler N.J., Li K.T., McLaren C.E., Parker R.J., and Fruehauf J.P. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol. Oncol. 87 (2002) 8-16
3. Mehta R.S., Bornstein R., Yu I.R., Parker R.K., McLaren C.E., Nguyen K.P., and Li K.T. Fruehauf. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res. Treat. 66 (2001) 225-237
4. Haroun R.I., Clatterbuck R.E., Gibbons M.C., Burger P.C., Parker R., Fruehauf J.P., and Brem H. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J. Neurooncol. 58 (2002) 115-123
5. Loizzi V., Chan K., Osann K., Cappiccini F., DiSaia P.J., and Berman M.L. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. 189 (2003) 1301-1307
6. d'Amato T.A., Pettiford B.L., Schuchert M.J., Parker R., Ricketts W.A., Luketich J.D., and Landreneau R.J. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy. Ann. Surg. Oncol. (2009) July 16 [Epub ahead of print, PMID: 19609620]
7. Kim H.S., Kim T.J., Chung H.H., Kim J.W., Kim B.G., Park N.H., Song Y.S., Bae D.S., and Kang S.B. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. J. Cancer Res. Clin. Oncol. (2009) May 16 [Epub ahead of print, PMID: 19449027]
8. Matsuo K., Bond V.K., Eno M.L., Im D.D., and Rosenshein N.B. Low drug resistance to both platinum and taxane chemotherapy on an in-vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian, and peritoneal cancer. Int. J. Cancer (2009) June 15 [Epub ahead of print, PMID: 19530239]
9. Matsuo K., Eno M.L., Im D.D., and Rosenshein N.B. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch. Gynecol. Obstet. (2009) May 20 [Epub ahead of print, PMID: 19455347]
10. McAlpine J.N., Eisenkop S.M., and Spirtos N.M. Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol. Oncol. 110 (2008) 360-364